Publication date: Jul 22, 2024
Therapeutic monoclonal antibodies (mAbs) have been studied in humans, but the impact on immune memory of mAb treatment during an ongoing infection has remained unclear. We evaluated the effect of infusion of the anti-SARS-CoV-2 spike receptor binding domain (RBD) mAb bamlanivimab on memory B cells (MBCs) in SARS-CoV-2-infected individuals. Bamlanivimab treatment skewed the repertoire of memory B cells targeting Spike towards non-RBD epitopes. Furthermore, the relative affinity of RBD memory B cells was weaker in mAb-treated individuals compared to placebo-treated individuals over time. Subsequently, after mRNA COVID-19 vaccination, memory B cell differences persisted and mapped to a specific reduction in recognition of the class II RBD site, the same RBD epitope recognized by bamlanivimab. These findings indicate a substantial role of antibody feedback in regulating memory B cell responses to infection, and single mAb administration can continue to impact memory B cell responses to additional antigen exposures months later.
| Concepts | Keywords |
|---|---|
| Antibodies | Bamlanivimab |
| Class | COVID-19 |
| Covid | mAb therapy |
| Months | memory B cells |
| Vaccination | SARS-CoV-2 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | vaccination |
| disease | IDO | cell |
| disease | MESH | infection |
| disease | VO | time |
| disease | MESH | COVID-19 |
| disease | IDO | site |